{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P10275",
      "entity_text" : "AR",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:15951529",
      "entity_text" : "enzalutamide",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "However, as ADT resistant prostate cancers are still sensitive to AR pathway signalling, and respond to the nonsteroidal anti-androgenic drug abiraterone acetate [XREF_BIBR], and AR antagonists like enzalutamide [XREF_BIBR], the more accurate term is CRPC.",
  "reading_complete" : "2020-08-05T22:34:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:20:53Z",
  "trigger" : "antagonists",
  "evidence" : [ "AR antagonists like enzalutamide" ],
  "pmc_id" : "6463399",
  "score" : 0
}